| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Expected but not Quantified |
|---|
| Creation Date | 2012-09-06 15:16:49 UTC |
|---|
| Update Date | 2022-03-07 02:51:36 UTC |
|---|
| HMDB ID | HMDB0014379 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | Reboxetine |
|---|
| Description | Reboxetine is an antidepressant drug used in the treatment of clinical depression, panic disorder and ADD/ADHD. Its mesylate (i.e. methanesulfonate) salt is sold under tradenames including Edronax, Norebox, Prolift, Solvex, Davedax or Vestra. Reboxetine has two chiral centers, but it only exists as two enantiomers, (R,R)-(-)- and (S,S)-(+)-reboxetine. |
|---|
| Structure | [H][C@]1(CNCCO1)[C@@H](OC1=CC=CC=C1OCC)C1=CC=CC=C1 InChI=1S/C19H23NO3/c1-2-21-16-10-6-7-11-17(16)23-19(15-8-4-3-5-9-15)18-14-20-12-13-22-18/h3-11,18-20H,2,12-14H2,1H3/t18-,19-/m0/s1 |
|---|
| Synonyms | | Value | Source |
|---|
| (SS)-Reboxetine | HMDB | | Reboxetine mesylate | HMDB | | 2-((2-Ethoxyphenoxy)benzyl)morpholine methanesulfonate | HMDB | | Vestra | HMDB | | (+)-(2S)-2-((S)-(2-Ethoxyphenoxy)phenylmethyl)morpholine | HMDB | | Reboxetine | MeSH |
|
|---|
| Chemical Formula | C19H23NO3 |
|---|
| Average Molecular Weight | 313.3908 |
|---|
| Monoisotopic Molecular Weight | 313.167793607 |
|---|
| IUPAC Name | (2S)-2-[(S)-2-ethoxyphenoxy(phenyl)methyl]morpholine |
|---|
| Traditional Name | reboxetine |
|---|
| CAS Registry Number | 98769-81-4 |
|---|
| SMILES | [H][C@]1(CNCCO1)[C@@H](OC1=CC=CC=C1OCC)C1=CC=CC=C1 |
|---|
| InChI Identifier | InChI=1S/C19H23NO3/c1-2-21-16-10-6-7-11-17(16)23-19(15-8-4-3-5-9-15)18-14-20-12-13-22-18/h3-11,18-20H,2,12-14H2,1H3/t18-,19-/m0/s1 |
|---|
| InChI Key | CBQGYUDMJHNJBX-OALUTQOASA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as phenol ethers. These are aromatic compounds containing an ether group substituted with a benzene ring. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Benzenoids |
|---|
| Class | Phenol ethers |
|---|
| Sub Class | Not Available |
|---|
| Direct Parent | Phenol ethers |
|---|
| Alternative Parents | |
|---|
| Substituents | - Phenoxy compound
- Phenol ether
- Alkyl aryl ether
- Aralkylamine
- Monocyclic benzene moiety
- Morpholine
- Oxazinane
- Dialkyl ether
- Secondary aliphatic amine
- Ether
- Oxacycle
- Secondary amine
- Organoheterocyclic compound
- Azacycle
- Organopnictogen compound
- Organonitrogen compound
- Organooxygen compound
- Hydrocarbon derivative
- Organic oxygen compound
- Organic nitrogen compound
- Amine
- Aromatic heteromonocyclic compound
|
|---|
| Molecular Framework | Aromatic heteromonocyclic compounds |
|---|
| External Descriptors | Not Available |
|---|
| Ontology |
|---|
| Not Available | Not Available |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | 170 - 171 °C (mesylate salt) | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | 0.022 g/L | Not Available | | LogP | 3.1 | Not Available |
|
|---|
| Experimental Chromatographic Properties | Experimental Collision Cross Sections| Adduct Type | Data Source | CCS Value (Å2) | Reference |
|---|
| [M+H]+ | CBM | 174.0 | 30932474 |
|
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 4.82 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 12.1966 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 2.75 minutes | 32390414 | | AjsUoB = Accucore 150 Amide HILIC with 10mM Ammonium Formate, 0.1% Formic Acid | 40.8 seconds | 40023050 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 1799.9 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 258.9 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 185.5 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 183.0 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 116.2 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 457.0 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 450.3 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 248.2 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 1003.4 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 457.0 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 1300.7 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 330.2 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 332.9 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 291.1 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 243.6 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 7.8 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| Reboxetine,1TMS,isomer #1 | CCOC1=CC=CC=C1O[C@@H](C1=CC=CC=C1)[C@@H]1CN([Si](C)(C)C)CCO1 | 2462.4 | Semi standard non polar | 33892256 | | Reboxetine,1TMS,isomer #1 | CCOC1=CC=CC=C1O[C@@H](C1=CC=CC=C1)[C@@H]1CN([Si](C)(C)C)CCO1 | 2438.0 | Standard non polar | 33892256 | | Reboxetine,1TMS,isomer #1 | CCOC1=CC=CC=C1O[C@@H](C1=CC=CC=C1)[C@@H]1CN([Si](C)(C)C)CCO1 | 3361.9 | Standard polar | 33892256 | | Reboxetine,1TBDMS,isomer #1 | CCOC1=CC=CC=C1O[C@@H](C1=CC=CC=C1)[C@@H]1CN([Si](C)(C)C(C)(C)C)CCO1 | 2689.3 | Semi standard non polar | 33892256 | | Reboxetine,1TBDMS,isomer #1 | CCOC1=CC=CC=C1O[C@@H](C1=CC=CC=C1)[C@@H]1CN([Si](C)(C)C(C)(C)C)CCO1 | 2620.6 | Standard non polar | 33892256 | | Reboxetine,1TBDMS,isomer #1 | CCOC1=CC=CC=C1O[C@@H](C1=CC=CC=C1)[C@@H]1CN([Si](C)(C)C(C)(C)C)CCO1 | 3477.0 | Standard polar | 33892256 |
|
|---|
| GC-MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted GC-MS | Predicted GC-MS Spectrum - Reboxetine GC-MS (Non-derivatized) - 70eV, Positive | splash10-002f-9510000000-c419747ac13882d22181 | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Reboxetine GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Reboxetine GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Reboxetine 10V, Positive-QTOF | splash10-03di-0129000000-8a66fcd9f27a2e8d1e29 | 2017-07-25 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Reboxetine 20V, Positive-QTOF | splash10-0h6r-1391000000-293a0b61cefb20d06e3d | 2017-07-25 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Reboxetine 40V, Positive-QTOF | splash10-05r3-9500000000-725ea11aada64c859bc4 | 2017-07-25 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Reboxetine 10V, Negative-QTOF | splash10-03di-1249000000-0355482034f887fdfb23 | 2017-07-26 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Reboxetine 20V, Negative-QTOF | splash10-03el-2693000000-66480f21ca5998c6d03c | 2017-07-26 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Reboxetine 40V, Negative-QTOF | splash10-0a4l-7900000000-b34a81b04900dc0e1282 | 2017-07-26 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Reboxetine 10V, Positive-QTOF | splash10-03di-0709000000-49770d96ddc33f490da6 | 2021-09-22 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Reboxetine 20V, Positive-QTOF | splash10-01tc-6912000000-89667ca9f247b109629a | 2021-09-22 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Reboxetine 40V, Positive-QTOF | splash10-002f-9600000000-500dfce79cc2fe29db26 | 2021-09-22 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Reboxetine 10V, Negative-QTOF | splash10-03di-0319000000-650b49e0d4835471204c | 2021-09-22 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Reboxetine 20V, Negative-QTOF | splash10-0a4i-0900000000-0085228a23971030ec0a | 2021-09-22 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Reboxetine 40V, Negative-QTOF | splash10-0a4i-4911000000-5c78e43b439b2c360e21 | 2021-09-22 | Wishart Lab | View Spectrum |
|
|---|
| General References | - Kasper S, el Giamal N, Hilger E: Reboxetine: the first selective noradrenaline re-uptake inhibitor. Expert Opin Pharmacother. 2000 May;1(4):771-82. [PubMed:11249515 ]
- Edwards DM, Pellizzoni C, Breuel HP, Berardi A, Castelli MG, Frigerio E, Poggesi I, Rocchetti M, Dubini A, Strolin Benedetti M: Pharmacokinetics of reboxetine in healthy volunteers. Single oral doses, linearity and plasma protein binding. Biopharm Drug Dispos. 1995 Aug;16(6):443-60. [PubMed:7579027 ]
- Wienkers LC, Allievi C, Hauer MJ, Wynalda MA: Cytochrome P-450-mediated metabolism of the individual enantiomers of the antidepressant agent reboxetine in human liver microsomes. Drug Metab Dispos. 1999 Nov;27(11):1334-40. [PubMed:10534319 ]
- Fleishaker JC: Clinical pharmacokinetics of reboxetine, a selective norepinephrine reuptake inhibitor for the treatment of patients with depression. Clin Pharmacokinet. 2000 Dec;39(6):413-27. [PubMed:11192474 ]
|
|---|